Comparison of Dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis

Dalbavancin is a lipoglycopeptide antibiotic that has a lipophilic side chain that gives it a long half-life, allowing weekly or every two weeks administration [1 –3]. It has been approved for the treatment of skin and soft tissue infections [2]. Its innovative posology could offer great advantages in the consolidation treatment of infections that require prolonged antibiotic treatment, such as infective endocarditis (IE), and osteoarticular infection [3– 5].

Source: International Journal of Infectious Diseases - November 4, 2023 Category: Infectious Diseases Authors: M Su árez, A Pérez-Landeiro, A Sanjurjo, O. Lima, A. Sousa, A. López, L. Martínez-Lamas, X. Cabrera, M Rubianes, MT Pérez-Rodríguez Source Type: research